amphetamine extended-release orally disintegrating tablets | News Search

跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

找到 42,871 条关于 “amphetamine extended-release orally disintegrating tablets”

Granules Pharmaceuticals Receives Tentative FDA Approval for Generic ADHD Treatment

Health Canada Approves Dyanavel XR Extended-Release Amphetamine for ADHD Treatment in Adults and Children

Viatris Launches First Clozapine Orally Disintegrating Tablet in Canada for Treatment-Resistant Schizophrenia

Biocon Pharma Receives FDA Approval for Tofacitinib Extended-Release Tablets

FDA Approves Femlyv, First Orally Disintegrating Birth Control Pill

Strides Pharma Secures USFDA Approval for Generic Theophylline Extended-Release Tablets

Elite Pharmaceuticals Secures FDA Approval for Generic Ropinirole Extended-Release Tablets for Parkinson's Disease

Strides Pharma Receives USFDA Approval for Generic Theophylline Extended-Release Tablets

Alembic Pharma Gains US FDA Approval for Generic Lamotrigine Extended-Release Tablets

Amneal's Pyridostigmine Bromide Extended-Release Tablets Receive FDA Approval for Nerve Agent Pretreatment

第 1 页，共 743 页